- Home
- CLLS vs GLO Comparison
CLLS vs GLO Comparison
Compare CLLS & GLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CLLS | GLO |
|---|---|---|
| Founded | 1999 | 2006 |
| Country | France | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 476.5M | 243.8M |
| IPO Year | 2007 | N/A |
Fundamental Metrics
Financial Performance| Metric | CLLS | GLO |
|---|---|---|
| Price | $4.45 | $5.83 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $8.50 | N/A |
| AVG Volume (30 Days) | 112.9K | ★ 170.5K |
| Earning Date | 11-07-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 11.38% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $82,551,000.00 | N/A |
| Revenue This Year | $32.58 | N/A |
| Revenue Next Year | $20.68 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 129.04 | N/A |
| 52 Week Low | $1.10 | $4.08 |
| 52 Week High | $5.48 | $5.18 |
Technical Indicators
Market Signals| Indicator | CLLS | GLO |
|---|---|---|
| Relative Strength Index (RSI) | 48.67 | 63.89 |
| Support Level | $4.37 | $5.65 |
| Resistance Level | $4.68 | $5.71 |
| Average True Range (ATR) | 0.25 | 0.05 |
| MACD | -0.05 | 0.02 |
| Stochastic Oscillator | 47.27 | 95.53 |
Price Performance
Historical ComparisonAbout CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.
About GLO Clough Global Opportunities Fund
Clough Global Opportunities Fund is a closed-end management investment company based in the United States. Its investment objective is to provide a high level of total return by investing in equity securities of companies of any market capitalization and equity-related securities, including equity swaps and call options, as well as fixed-income securities, including both corporate and sovereign debt, in both U.S. and non-U.S. markets.